CervoMed Inc. (NASDAQ:CRVO) Stock Has Average Target Price of $21.00

Shares of CervoMed Inc. (NASDAQ:CRVO – Get Free Report) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $21.00.

CRVO has been the subject of several research reports. Weiss Ratings downgraded CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Chardan Capital upgraded CervoMed to a “strong-buy” rating in a report on Monday, August 3rd. HC Wainwright reissued a “buy” rating on shares of CervoMed in a research report on Monday, October 5th. Wall Street Zen raised CervoMed from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Roth Capital set a $7.00 price target on CervoMed in a report on Thursday, August 20th.

Read Our Latest Report on CRVO

CervoMed Price Performance

Shares of NASDAQ CRVO opened at $1.46 on Friday. CervoMed has a 12-month low of $1.27 and a 12-month high of $10.00. The company has a market capitalization of $22.09 million, a PE ratio of -0.53 and a beta of -0.62. The firm’s 50-day moving average is $2.24 and its two-hundred day moving average is $3.20.

CervoMed (NASDAQ:CRVO – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. On average, analysts forecast that CervoMed will post -2.04 EPS for the current fiscal year.

Insider Activity at CervoMed

In related news, CEO John J. Alam acquired 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 18th. The shares were acquired at an average price of $1.53 per share, with a total value of $153,000.00. Following the completion of the purchase, the chief executive officer directly owned 1,584,078 shares in the company, valued at approximately $2,423,639.34. The trade was a 6.74% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 35.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new position in CervoMed in the 1st quarter valued at about $252,000. BlackRock Inc. acquired a new stake in shares of CervoMed during the 2nd quarter worth about $167,000. Byrne Asset Management LLC grew its holdings in shares of CervoMed by 248.6% during the second quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock worth $159,000 after buying an additional 36,550 shares in the last quarter. Citizens Financial Group Inc. RI purchased a new stake in shares of CervoMed during the second quarter worth about $116,000. Finally, Caprock Group LLC purchased a new stake in shares of CervoMed during the third quarter worth about $34,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.

CervoMed Company Profile

(Get Free Report)

CervoMed is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on therapies intended to address underlying disease processes rather than only manage symptoms. The company’s lead drug candidate, neflamapimod, is an oral, brain-penetrant small molecule designed to inhibit p38 alpha mitogen-activated protein kinase. CervoMed has studied the candidate for dementia with Lewy bodies, a progressive neurodegenerative disorder. CervoMed was formed in 2023 when EIP Pharma combined with Diffusion Pharmaceuticals, which subsequently adopted the CervoMed name.

See Also

Analyst Recommendations for CervoMed (NASDAQ:CRVO)

Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.